A new version of this title is available
This publication is provided for historical reference only and the information may be out of date.
- Anti-CS
Anti circumsporozoite antibody
- ACT
artemisinin-based combination therapy
- AE
Adverse Event
- AEFI
Adverse Event Following Immunization
- AESI
Adverse Event of Special Interest
- ANC
antenatal care
- AVPU
Alert, Voice, Pain, Unresponsive
- BCC
behaviour change communication
- bw
body weight
- CI
confidence interval
- CIDG
Cochrane Infectious Diseases Group
- DALY
disability adjusted life year
- DHIS2
District Health Information Software 2
- DTP
diphtheria, tetanus and pertussis (vaccine)
- EIR
entomological inoculation rate
- EPI
Expanded Programme on Immunization
- EtD
evidence to decision framework
- GDG
Guidelines Development Group
- GMP
Global Malaria Programme
- GPIRM
Global plan for insecticide resistance management
- GRADE
Grading of Recommendations Assessment, Development and Evaluation
- GTS
Global technical strategy for malaria 2016 - 2030
- G6PD
glucose-6-phosphate dehydrogenase
- HBHI
High burden to high impact approach
- HRP2
histidine-rich protein 2
- ICER
incremental cost-effectiveness ratio
- IPTi
intermittent preventive treatment in infants
- IPTp
intermittent preventive treatment in pregnancy
- IRM
insecticide resistance management
- IRS
indoor residual spraying
- IOS
International Organization for Standardization
- ITN
insecticide-treated net
- ITPS
insecticide-treated plastic sheeting
- IVB
WHO Department for Immunization, Vaccines and Biologicals
- IVM
integrated vector management
- LLIN
long-lasting insecticidal net
- LSM
larval source management
- M&E
monitoring and evaluation
- MPAG
Malaria Policy Advisory Group (previously Malaria Policy Advisory Committee)
- MVIP
WHO Malaria Vaccine Implementation Programme
- NAAT
nucleic acid amplification test
- NMP
national malaria programme
- NSP
national (malaria) strategic plan
- PBO
piperonyl butoxide
- PCR
polymerase chain reaction
- PfHRP2
Plasmodium falciparum histidine-rich protein-2
- PICO
population, participants or patients; intervention or indicator; comparator or control; outcome
- PPC
preferred product characteristic
- PQ
prequalification (WHO)
- pLDH
parasite-lactate dehydrogenase
- Pvdhfr
Plasmodium vivax dihydrofolate reductase gene
- PYAR
person-years at risk
- QC
quality control
- RCT
randomized controlled trial
- RDT
rapid diagnostic test
- RR
relative risk, or risk ratio
- SP
sulfadoxine–pyrimethamine
- SP + AQ
sulfadoxine-pyrimethamine + amodiaquine
- SMC
seasonal malaria chemoprevention
- TES
therapeutic efficacy study
- VCAG
Vector Control Advisory Group
- VCTEG
Technical Expert Group on Malaria Vector Control
- WHO
World Health Organization
Publication Details
Copyright
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.
Some rights reserved. This work is available under the Creative Commons AttributionNonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).
Under the terms of this license, you may copy, redistribute and adapt the work for noncommercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.
Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.
Publisher
World Health Organization, Geneva
NLM Citation
WHO Guidelines for malaria [Internet]. Geneva: World Health Organization; 2022 Feb 18. 1, ABBREVIATIONS.